Alx Oncology Holdings
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Alx Oncology Holdings .
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 1.10 $ to 2.60 $ · Last price: 1.40 $ (As of: September 28, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/29/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Alx Oncology Holdings ALXO | 0.2 | – | -2.3 | – | 0.0 | – | -25.7 |
| Vertex Pharmaceuticals Inc VRTX | 133.5 | 32.0 | 24.4 | 55.0 | 38.1 | 9.6 | 36.8 |
| Moderna Inc MRNA | 78.3 | – | 4.6 | -66.0 | -131.1 | -39.2 | 708.1 |
| Regeneron Pharmaceuticals Inc REGN | 78.2 | 18.9 | 13.5 | 44.5 | 20.7 | 1.0 | 34.1 |
| argenx NV ARGX | 60.5 | 37.2 | 30.7 | 59.1 | 32.0 | 89.6 | 36.6 |
| Revolution Medicines Inc RVMD | 41.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 359.3 |
| BeiGene, Ltd. ONC | 41.5 | 65.5 | 32.4 | 88.9 | 19.1 | 40.2 | 12.6 |
| Alnylam Pharmaceuticals Inc ALNY | 33.9 | 64.3 | 28.6 | 79.7 | 23.0 | 65.2 | -42.8 |
| Royalty Pharma Plc RPRX | 32.2 | 31.5 | 19.2 | 95.8 | 100.3 | 5.1 | 70.0 |
| Median of companies shown | 41.9 | 34.6 | 19.2 | 57.0 | 20.7 | 7.3 | 36.6 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | 2 | -14 | -14 | -0.63 | -13 | 9 | 11 |
| 2019 | 5 | -19 | -19 | -0.88 | -14 | 0 | 11 |
| 2020 | 1 | -44 | -46 | -1.15 | -38 | 430 | 436 |
| 2021 | 0 | -84 | -83 | -2.07 | -68 | 363 | 380 |
| 2022 | 0 | -127 | -123 | -3.03 | -89 | 263 | 306 |
| 2023 | 0 | -170 | -161 | -3.74 | -130 | 190 | 243 |
| 2024 | 0 | -142 | -135 | -2.58 | -122 | 114 | 148 |
| 2025 | 0 | -104 | -102 | -1.90 | -84 | 26 | 59 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q3 | -0.58 | 53.20 | 0 | – | – | -25 | -26 |
| 2024: Q4 | -0.44 | 52.70 | 1 | -65.00 | -3,359.80 | -32 | -32 |
| 2025: Q1 | -0.48 | 32.80 | 0 | – | – | -25 | -25 |
| 2025: Q2 | -0.44 | 29.00 | 0 | – | – | -23 | -24 |
| 2025: Q3 | -0.41 | 29.30 | 0 | – | – | -17 | -17 |
| 2025: Q4 | -0.37 | 16.00 | 0 | -100.00 | – | -19 | -19 |
| 2026: Q1 | -0.17 | 64.40 | 0 | – | – | -19 | -19 |
| 2026: Q2 | -0.13 | 70.50 | 0 | – | – | -35 | -35 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Growth
Quality & Balance Sheet
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.64 | -3.58 – -1.70 | 0 | -59.5% | 2 |
| 12/31/2027 | -0.55 | -0.74 – -0.40 | 0 | 17.1% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -100.0%
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -391.4%
- ROCE > 15% -301.6%
- Expected return > 10% –
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Sell | 2,230 | 1.93 | 4,304 |
| Aug 17, 2026 | Wong Shelly | SVP, FINANCE AND CAO | Sell | 573 | 1.93 | 1,106 |
The company
About the Company
ALX Oncology Holdings Inc. ist ein Immunonkologieunternehmen im klinischen Stadium, das sich auf die Entwicklung von Therapien für Krebspatienten in den Vereinigten Staaten konzentriert. Der führende Produktkandidat des Unternehmens ist Evorpacept, ein CD47-blockierendes biologisches Therapeutikum, das als Kombinationstherapie mit weiteren Krebswirkstoffen entwickelt wird, darunter ASPEN-06, das sich in einer Phase-2-Studie zur Behandlung von Magen-/GEJ-Krebs befindet. Das Unternehmen hat Kooperationsvereinbarungen für Evorpacept-Kombinationsprogramme, darunter mit Jazz Pharmaceuticals plc zu Zanidatamab in einer Phase-1b/2-Studie zur Behandlung von Brustkrebs und weiteren soliden Tumoren; HER2 mit einem ADC, Fam-Trastuzumab-Deruxtecan-nxki, in einer Phase-1-Studie zur Behandlung von Patienten mit Brustkrebs; ALX2004 in einer Phase-1-Studie zur Behandlung solider Tumoren; dem MD Anderson Cancer Center mit Rituximab und Lenalidomid zur Behandlung von Patienten mit indolentem und aggressivem NHL; sowie mit Sanofi zu Isatuximab und Dexamethason in einer Phase-1/2-Studie zur Behandlung von Patienten mit rezidiviertem oder refraktärem Multiplem Myelom. Es bestehen Lizenzvereinbarungen mit dem Board of Trustees of Leland Stanford Junior University. Das Unternehmen wurde 2015 gegründet und hat seinen Hauptsitz in South San Francisco, Kalifornien.
- Employees
- 48
- Headquarters
- South San Francisco, CA
- Address
- 323 Allerton Avenue, 94080 South San Francisco, United States
- Phone
- 650 466 7125
- Website
- alxoncology.com
- IPO Date
- 07/17/2020
- ISIN
- US00166B1052
Management
| Name | Title | Birth Year |
|---|---|---|
| Jason W. Lettmann | CEO & Director | 1977 |
| Harish Shantharam C.F.A. | Chief Financial Officer | 1981 |
| Shelly Wong CPA | Senior VP of Finance & Chief Accounting Officer | 1977 |
| Barbara J. Klencke M.D. | Chief Medical Officer | 1957 |
| Jeff E. Knight M.P.H. | Chief Development & Operating Officer | 1972 |
| Michael Listgarten | General Counsel | – |
| Athanasios Tsiatis M.D. | Senior Vice President of Clinical Development | – |
| Lin Yeong-Liang M.D., M.S. | Senior Vice President of Drug Safety & Pharmacovigilance | – |
| Lisa Sauer | Senior Vice President of Regulatory Affairs & Quality Assurance | – |
| Sue Naim | Senior Vice President of Clinical Operations | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.